Edwards Lifesciences (NYSE:EW) Shares Acquired Rep. Bruce Westerman

Representative Bruce Westerman (R-Arkansas) recently bought shares of Edwards Lifesciences Co. (NYSE:EW). In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Edwards Lifesciences stock on March 3rd. The trade occurred in the Representative’s “FISHER IRA” account.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of LVMH Moët Hennessy – Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/2/2025.
• Purchased $1,001 – $15,000 in shares of Sony Group (NYSE:SONY) on 3/24/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi UFJ Financial Group (NYSE:MUFG) on 3/21/2025.
• Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 3/21/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/20/2025.

Edwards Lifesciences Stock Up 0.5 %

Shares of Edwards Lifesciences stock opened at $71.56 on Friday. The business’s 50 day simple moving average is $71.31 and its 200 day simple moving average is $70.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $42.07 billion, a PE ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the transaction, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,153,526.69. This trade represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock valued at $5,163,062 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Truist Financial dropped their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a report on Friday, April 11th. Piper Sandler boosted their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $78.55.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Harbor Capital Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after buying an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its holdings in shares of Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after buying an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $3,702,000. Finally, Avanza Fonder AB acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $4,845,000. Institutional investors own 79.46% of the company’s stock.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.

Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.